Terray Therapeutics focuses on discovering and developing small molecule drugs using a combination of experimental techniques and computational methods. The company generates a large dataset of over two billion unique target-ligand binding measurements, adding 150 million new measurements each month. This extensive data allows for precise predictions of molecular properties through deep learning models. Terray employs a fast design-make-test-analyze cycle, completing each cycle in under a month, which enables efficient exploration of chemical compounds and rapid identification of effective small molecules for various therapeutic targets. While the primary focus is on immunology, Terray collaborates with pharmaceutical and biotech companies to tackle a wide range of therapeutic challenges, creating additional revenue opportunities alongside its own drug discovery initiatives.